Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16

Damian Garde

In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Therapeutics and Therapeutics widened their R&D operations, while some smaller players signed deals and roped in cash to keep their projects moving.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS